Zimmer Biomet Continues Turnaround Lead by ROSA Robot
Zimmer Biomet’s net sales were up 1.2% year-over-year in the second quarter. CEO Bryan Hanson said the ROSA Knee robotic surgery system is performing even better than expected since it launched earlier this year, and is expected to be an important revenue-driver in the future.
You may also be interested in...
Knees Boost Zimmer Biomet; Turnaround Continues, But FDA Woes Linger
Zimmer Biomet reported Q4 results that reflected solid progress in the company’s turnaround efforts, with knees leading the charge. But the company is making slower-than-expected progress resolving FDA warning letter issues and faces a new bribery lawsuit in Mexico.
More Than Mako: Stryker Delivers Strong Growth In All Three Businesses
Stryker’s revenues grew 8.1% in 2019, its seventh consecutive year of accelerating organic growth and 40th year of sales growth. All three of the company’s major divisions grew in the high single-digits, led by sales of neurotechnology and spine products.
Software Issue Brings Recall Of Zimmer ROSA
Zimmer Biomet has issued a recall on its ROSA Brain 3.0 software platform due to a software issue that could cause patient injury.